About zymeworks - ZYME
Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Zanidatamab's unique binding properties result in multiple mechanisms of action that may enable it to address unmet need in patient populations with HER2-expressing cancers. The company was founded on September 8, 2003 and is headquartered in Middletown, DE.
ZYME At a Glance
Zymeworks, Inc.
108 Patriot Drive
Middletown, Delaware 19709
| Phone | 1-302-274-8744 | Revenue | 76.01M | |
| Industry | Pharmaceuticals: Major | Net Income | -118,674,000.00 | |
| Sector | Health Technology | Employees | 277 | |
| Fiscal Year-end | 12 / 2024 | |||
| View SEC Filings |
ZYME Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 9.413 |
| Price to Book Ratio | 1.582 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -3.047 |
| Enterprise Value to Sales | 4.84 |
| Total Debt to Enterprise Value | 0.073 |
ZYME Efficiency
| Revenue/Employee | 274,411.552 |
| Income Per Employee | -428,425.993 |
| Receivables Turnover | 3.903 |
| Total Asset Turnover | 0.124 |
ZYME Liquidity
| Current Ratio | 7.405 |
| Quick Ratio | 7.405 |
| Cash Ratio | 6.713 |
ZYME Profitability
| Gross Margin | 77.234 |
| Operating Margin | -181.62 |
| Pretax Margin | -156.873 |
| Net Margin | -156.125 |
| Return on Assets | -19.303 |
| Return on Equity | -24.782 |
| Return on Total Capital | -24.144 |
| Return on Invested Capital | -23.616 |
ZYME Capital Structure
| Total Debt to Total Equity | 5.749 |
| Total Debt to Total Capital | 5.437 |
| Total Debt to Total Assets | 4.60 |
| Long-Term Debt to Equity | 4.832 |
| Long-Term Debt to Total Capital | 4.57 |